Skip to main content
TipRanks
Go Ultimate75% OFF

Joel Debellefeuille Insider Profile

4 Followers

Joel Debellefeuille, former Director at Primo Nutraceuticals, holds 483.40K shares in Primo Nutraceuticals (Ticker: BUGVF).

Joel Debellefeuille's Trading History

BUGVF
Primo Nutraceuticals
Oct 16, 2020―Uninformative Buy42.00K$53.17K
BUGVF
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Oct 16, 2020Uninformative BuyC$42.00K350,000C$0.12――
Sep 15, 2020Uninformative BuyC$10.00K133,333C$0.08――
Sep 12, 2020Informative SellC$2.70K270,000C$0.01+69.80%―
Sep 12, 2020Informative SellC$0.00115,000C$0.00+69.80%―
Jul 18, 2020Uninformative BuyC$6.75K450,000C$0.02――

You May Also Like

Joel Debellefeuille insider profile FAQ

What is the percentage of profitable transactions made by Joel Debellefeuille?
The percentage of profitable transactions made by Joel Debellefeuille is 100%.
What is the average return per transaction made by Joel Debellefeuille?
The average return per transaction made by Joel Debellefeuille is 58.60%.
What stocks does Joel Debellefeuille hold?
Joel Debellefeuille holds: BUGVF stocks.
What was Joel Debellefeuille’s latest transaction?
Joel Debellefeuille’s latest transaction was an Uninformative Buy of $42.00K.
What was Joel Debellefeuille's most profitable transaction?
Joel Debellefeuille’s most profitable transaction was an Informative Sell of BUGVF stock on September 12, 2020. The return on the trade was 69.80%.
What is Joel Debellefeuille's role in Primo Nutraceuticals?
Joel Debellefeuille's role in Primo Nutraceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.